Díaz Santos E, Mora Jiménez C, Del Río-Carbajo L, Vidal-Cortés P
Medicina Intensiva, Consorci Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain; Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Medicina Intensiva, Consorci Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain.
Med Intensiva (Engl Ed). 2022 Sep;46(9):508-520. doi: 10.1016/j.medine.2022.06.014. Epub 2022 Jul 12.
Pseudomonas aeruginosa is the microorganism most frequently involved in the main ICU-acquired infections, with special importance in ventilator associated pneumonia. Its importance lies, in addition to its high incidence in critically ill patients, in the severity of the infections it causes and in the difficulty of its antimicrobial treatment, directly related to the high percentage of resistance to antibiotics classically considered first-line. New active antibiotics have recently been developed against Pseudomonas aeruginosa, even against multi-drug resistant strains. This review analyzes both the differential characteristics of Pseudomonas aeruginosa infections and the new therapeutic options, focusing on multi-drug resistant Pseudomonas aeruginosa.
铜绿假单胞菌是重症监护病房（ICU）获得性主要感染中最常涉及的微生物，在呼吸机相关性肺炎中尤为重要。其重要性不仅在于它在重症患者中的高发病率，还在于它所引起感染的严重性以及抗菌治疗的困难程度，这直接与对传统上被视为一线抗生素的高耐药率相关。最近已研发出针对铜绿假单胞菌，甚至针对多重耐药菌株的新型活性抗生素。本综述分析了铜绿假单胞菌感染的不同特征以及新的治疗选择，重点关注多重耐药铜绿假单胞菌。
